US EditionAstraZeneca’s (AZN) Buy Rating Reaffirmed at Berenberg Bank
Summary by themarketsdaily.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
AstraZeneca’s (AZN) Buy Rating Reaffirmed at Berenberg Bank
Berenberg Bank restated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research note released on Friday, MarketBeat reports. The brokerage currently has a GBX 140 ($1.86) price target on the biopharmaceutical company’s stock. Several other analysts also recently issued reports on AZN. Shore Capital restated a “buy” rating on shares […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
